Know Cancer

forgot password

Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy

18 Years
Open (Enrolling)
Chronic Myeloid Leukemia

Thank you

Trial Information

Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy

This is a randomized, controlled pilot study to introduce eMedonline telemonitoring
technology to CML patients taking Gleevec or Tasigna. eMedonline will be used to
automatically collect time-dose specific medication data for individual patients, including
dosing times, missed doses, adverse events and e-diary data. All data will be available to
research staff for remote review via Web interface. Adverse events and non-adherence will
prompt interventions including supportive care counseling.

Inclusion Criteria:

- Patients 18 years of age or older.

- Pathologically documented diagnosis of Chronic Phase CML (Ph+) in whom treating
physician has determined that treatment with imatinib or nilotinib is appropriate

- Patients currently receiving Gleevec (imatinib) 300-600 mg daily or Tasigna
(nilotinib) 300-400 mg twice daily

- Known performance status 0,1 or 2 (ECOG)

- Known adequate end organ function, defined as:

- Total bilirubin < 1.5 xULN

- SGOT and SGPT <2.5 x ULN

- Creatinine < 1.5 x ULN

- ANC > 1.5

- Platelets > 100,000

- Patient is able to read and speak English

- Patient is willing and able to use a cell phone

- Written, voluntary informed consent

Exclusion Criteria:

- Patient with any significant history of non-compliance to medical regimens or with
inability to grant reliable informed consent

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Outcome Measure:

eMedonline will be used to measure non-compliance in taking oral drug regimens.

Outcome Description:

Patients are stratified to one of two groups: Group 1 is patients on Gleevec or Tasigna who have been on drug less than 6 months; Group 2 is patients on Gleevec or Tasigna who have been on drug for equal to or more than 6 months. Group 1 is then divided into 2 groups: one using eMedonline for 3 months and the other not using eMedonline for 3 months. A crossover survey and pill counts will be done at the 3 month timepoint and then the groups will switch their access status to eMedonline.

Outcome Time Frame:

at 6 months, non-compliance will be measured in each arm of study

Safety Issue:


Principal Investigator

Robert Wehbie, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Rex Cancer Center - Wakefield


United States: Institutional Review Board

Study ID:




Start Date:

April 2009

Completion Date:

December 2014

Related Keywords:

  • Chronic Myeloid Leukemia
  • Chronic Myeloid Leukemia
  • Chronic Phase CML
  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive



Rex Cancer CenterRaleigh, North Carolina  27607
Rex Cancer Center - WakefieldRaleigh, North Carolina  27614
UNC HealthcareChapel Hill, North Carolina  27599